Connect with us

Business

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site

Published

on

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site


The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025.

Mike Blake | Reuters

Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the Trump administration to make the medicine more accessible.

The announcement also comes weeks after chief rival Novo Nordisk unveiled additional discounts on the cash prices of its obesity and diabetes drugs. 

Starting Monday, cash-paying patients with a valid prescription can get the starting dose of Zepbound vials for as low as $299 per month on LillyDirect, down from a previous price of $349 per month. They can also access the next dose, 5 milligrams, for $399 per month and all other doses for $449 per month, down from $499 per month across those sizes. 

Zepbound carries a list price of roughly $1,086 per month. That price point, and spotty insurance coverage for weight loss drugs in the U.S., have been significant barriers to access for some patients. 

Eli Lilly’s announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to get and afford. The agreements will cut the prices the government pays for the drugs, introduce Medicare coverage of obesity drugs for the first time for certain patients and offer discounted medicines on the government’s new direct-to-consumer website launching in January, TrumpRx. 

But Eli Lilly’s deal with Trump centers around lowering the prices of a different form of Zepbound – a multi-dose pen – after it wins Food and Drug Administration approval. 

That means Eli Lilly’s Monday announcement around cutting prices on the existing single-dose vials could allow more patients to get discounted treatments more quickly. 

“We will keep working to provide more options — expanding choices for delivery devices and creating new pathways for access — so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement. 

Eli Lilly’s stock, which has climbed more than 36% this year, fell nearly 2% on Monday. Its meteoric rise due to the success of Zepbound and its diabetes injection Mounjaro vaulted it to becoming the first health-care company to hit a $1 trillion market value last month. Though cutting prices means lower revenue per medication sold, Eli Lilly’s sales — and shares — have continued to soar through past pricing announcements as demand balloons.

With single-dose vials, patients need to use a syringe and needle to draw up the medicine and inject it into themselves. Eli Lilly first introduced that form of Zepbound in August 2024. 

It’s unclear how many patients are currently using single-dose vials of Zepbound. But Eli Lilly previously said that direct-to-consumer sales now account for more than a third of new prescriptions of Zepbound. 

Novo Nordisk earlier this month lowered the price of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients to $349 per month from $499 per month. That excludes the highest dose of Ozempic. 

The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment. 



Source link

Business

Rs 20,000 crore gold, silver rush: What will people buy this Akshaya Tritiya? – The Times of India

Published

on

Rs 20,000 crore gold, silver rush: What will people buy this Akshaya Tritiya? – The Times of India


This Akshaya Tritiya, India’s gold and silver markets are heading for bumper purchases, with overall trade likely to cross Rs 20,000 crore even as record-high prices reshape buying patterns. The estimate, shared by the Confederation of All India Traders (CAIT), is higher than last year’s Rs 16,000 crore, signalling growth in value despite a sharp rise in bullion rates.Prices for the yellow metal have surged sharply over the past year, going from Rs 1,00,000 per 10 grams, to Rs 1.58 lakh. Meanwhile, silver has shown a steeper rally, jumping from Rs 85,000 per kilogram to Rs 2.55 lakh per kilogram. According to CAIT, this sharp escalation has not weakened demand, but is instead prompting consumers to make more deliberate and value-oriented purchases.Praveen Khandelwal, member of parliament from Chandni Chowk and secretary general of CAIT told ANI, “Akshaya Tritiya has traditionally been one of India’s most auspicious occasions for purchasing gold… While gold continues to dominate, the nature of purchasing is evolving significantly in response to steep price escalation.”Commenting on customer preference, CAIT national president BC Bhartia highlighted, “There is a clear shift towards lightweight, wearable jewellery, alongside a stronger focus on silver and diamond products. Attractive incentives such as reduced making charges and complimentary gold coins are also helping sustain consumer interest.”Despite the increase in overall trade value, the quantity of metals being sold tells a different story. Pankaj Arora, National President of the All India Jewellers and Goldsmith Federation (AIJGF), an associate of CAIT, explained that the projected Rs 16,000 crore gold trade amounts to nearly 10,000 kilograms (10 tonnes) at current rates. The value, spread across an estimated 2 to 4 lakh jewellers, translates to average sales of only 25 to 50 grams per jeweller, “clearly indicating a sharp decline in volume”.Meanwhile for silver, the estimated Rs 4,000 crore trade corresponds to around 1,56,800 kilograms (157 tonnes), resulting in average sales of about 400 to 800 grams per jeweller during the festival period. “These figures underline a critical shift: while the value of business is expanding due to rising prices, actual consumption is contracting,” Khandelwal said.This gap between value and volume is also reshaping consumer’s buying pattern, with smaller items and lightweight jewellery gaining popularity. At the same time, jewellers are facing challenges due to fluctuating prices, especially when it comes to managing inventory.Even so, festive demand remains steady, with markets witnessing healthy footfall. “Consumers are now adopting a more cautious and pragmatic approach, balancing traditional beliefs with financial discipline,” Khandelwal added.At the same time, it’s not just about physical gold anymore as consumers are increasingly exploring alternatives like digital gold, Sovereign Gold Bonds and gold ETFs, drawn by the promise of liquidity, safety and flexibility when prices are volatile.CAIT and AIJGF have urged jewellers to comply with mandatory hallmarking standards, including HUID certification, and advised buyers to verify the purity and authenticity of their purchases.



Source link

Continue Reading

Business

The cost of rising rents: Working four jobs and pushed on to benefits

Published

on

The cost of rising rents: Working four jobs and pushed on to benefits



Lauren Elcock is among the young Londoners who say rising rents are forcing them to quit the capital.



Source link

Continue Reading

Business

Scams have grown more sophisticated, but people are fighting back

Published

on

Scams have grown more sophisticated, but people are fighting back


As governments across the world restricted the movements of their citizens during Covid lockdowns from 2020, people spent more time online. We bought more online and socialised more online, and this brought us closer to the people who want to scam us. At the same time, realistic video impersonations, voices, websites, and texts became more commonplace, and scammers increased their use of social media including WhatsApp.



Source link

Continue Reading

Trending